Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally

On May 15, 2026, Cormorant Asset Management disclosed a new position Dianthus Therapeutics (NASDAQ:DNTH)acquires 950,000 shares in a trade valued at $55.01 million based on quarter-to-quarter prices.

What’s going on

According to a Securities and Exchange Commission (SEC) filing dated May 15th, 2026, Cormorant Asset Management added a new position in Dianthus Therapeutics by buying 950,000 shares. The estimated transaction value was $55.01 million based on the average closing price for the quarter. The quarter-end position was estimated at $79.72 million, taking into account both acquisitions and subsequent price movements.

Another thing you need to know

• This was Cormorant’s new position, which now accounts for 4% of the 13F AUM reported as of March 31, 2026.

• Top five participants after completing:

  • NASDAQ:PRAX: $285.30 million (14.4% of AUM)

  • NASDAQ:BBOT: $160.01 million (8.1% of AUM)

  • NASDAQ:EYPT: $106.54 million (5.4% of AUM)

  • NASDAQ:EWTX: $102.69 million (5.2% of AUM)

  • NASDAQ:ERAS: $93.84 million (4.7% of AUM)

• As of May 14, 2026, shares of Dianthus Therapeutics are trading at $85.34, up 350% over the past year and outperforming the S&P 500, which is up nearly 25% instead.

Company Overview

Company summary

• Dianthus Therapeutics develops and develops novel monoclonal antibody therapies, with DNTH103 targeting severe autoimmune and inflammatory diseases such as generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory polyneuropathy.

• The company operates a clinical-stage biotechnology business model that focuses on the research and development of proprietary biologic therapies.

• It serves patients suffering from rare and severe autoimmune and neuromuscular diseases, with the main customers expected to be healthcare providers, hospitals, and specialized clinics that treat these conditions.

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in New York City, focused on the development of novel monoclonal antibody therapies for severe autoimmune and inflammatory diseases. The company uses a focused R&D approach to address unmet medical needs in neuromuscular disorders. Its strategy is focused on developing its lead candidate, DNTH103, through clinical trials to gain a competitive position in the specialty treatment market.

What this transaction means for investors

With shares of Dianthus up 350% in the past year (and more than doubling in the past quarter alone), Cormorant is still aggressively stepping in, suggesting the fund believes the clinical milestones could continue to be on the upside.

Dianthus has given investors a lot to watch lately. Earlier this month, the company said it had reached an early “GO” decision on its Phase 3 CAPTIVATE trial after an onslaught of faster-than-expected responses, something executives cited as evidence that the drug’s lead claseprubart may have “significantly morbid” potential. The company also said its standard myasthenia gravis Phase 3 trial will still start in mid-2026, with additional data on multifocal motor neuropathy expected later this year.

Dianthus ended the quarter with about $1.2 billion in revenue after raising about $719 million earlier this year, giving it a projected trajectory to enter 2030. That kind of balance sheet strength is important in biotech, where financing risks can derail even promising pipelines.

After such a big rally, expectations are now very high, but this fill suggests that Dianthus may have more room to work.

Should you buy stock in Dianthus Therapeutics right now?

Before buying stock in Dianthus Therapeutics, consider the following:

I The Motley Fool Stock Advisor a team of analysts has just identified what they believe to be 10 best stocks for investors to buy now… and Dianthus Therapeutics was not one of them. The 10 stocks that made the cut could produce huge gains in the coming years.

Think about when Netflix made this list on December 17, 2004… if you invested $1,000 during our recommendation, you will have $469,293!* Whenever Nvidia made this list on April 15, 2005… if you invested $1,000 during our recommendation, you will have $1,381,332!*

Now, it’s worth noting Stock Advisor’s the average total return is 993% – outperformed the market by 207% for the S&P 500. Don’t miss the latest top 10 list, available via Stock Advisorand join an investment community built by individual investors for individual investors.

See 10 stocks »

*Stock Advisor returns as of May 17, 2026.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a policy of disclosure.

Why This Fund Just Made a $55 Million Bet on Dianthus Amid a 350% Stock Rally was originally published by The Motley Fool.